Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide that was being developed for inflammatory bowel diseases (IBD). ... Read more
Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting read more
Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference read more
Protagonist Therapeutics Reports Granting of Inducement Award read more
There are currently no events scheduled.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|